Impact on diabetes control and patient-reported outcomes of a newer implantable continuous glucose monitoring system (Eversense ® CGM System): a single-centre retro- and prospective observational study
CONCLUSIONS: The use of the Eversense® CGM System resulted in changes in HbA1c of between -0.2% and -0.45%. The rate of premature sensor breakdown was low. Major complications following sensor implantation or removal were absent, apart from one case of infection and four cases of complicated removal. Patient-reported outcomes with the Eversense® CGM System showed a subjective positive impact on hypoglycaemia rates, greater confidence in managing hypoglycaemia and diabetes in general, and easy handling of the transmitter and mobile app. Technical issues must be considered but are nowadays, with the use of the newest sensor generation, very rare.PMID:38579290 | DOI:10.57187/s.3366
Source: Swiss Medical Weekly - Category: General Medicine Authors: None Dimitri Guy Rohner None Lukas Burget None Christoph Henzen None Stefan Fischli Source Type: research
More News: Bleeding | Diabetes | Diabetes Mellitus | Diabetes Type 1 | Endocrinology | General Medicine | Information Technology | Study | Switzerland Health